Salvage therapies for PSMA PET-positive nodal recurrent prostate cancer

Salvage therapies for PSMA PET-positive nodal recurrent prostate cancer

Bibliographic Details
Main Authors:	A. Kretschmer, A. Buchner, C. Eze, P. Rogowski, C. Schäfer, H. Ilhan, M. Li, W.P. Fendler, P. Bartenstein, U. Ganswindt, C.G. Stief, C. Belka, N. Schmidt-Hegemann
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320334005

Similar Items

Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy
by: Nina-Sophie Schmidt-Hegemann, et al.
Published: (2017-11-01)

Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy
by: Nina-Sophie Schmidt-Hegemann, et al.
Published: (2018-03-01)

Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design
by: Alexander Kretschmer, et al.
Published: (2021-06-01)

Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
by: Nina-Sophie Schmidt Hegemann, et al.
Published: (2020-11-01)

A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa
by: Nina-Sophie Schmidt-Hegemann, et al.
Published: (2021-10-01)

Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
by: Ann-Kathrin Oehus, et al.
Published: (2020-04-01)

Total Tumor Volume on18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with225 Ac-PSMA-I&T
by: Albert, N.L, et al.
Published: (2022)

Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
by: Jeremie Calais, et al.
Published: (2019-01-01)

Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
by: Jeremie Calais, et al.
Published: (2019-01-01)

PSMA PET/CT to guide salvage treatment post prostatectomy: The IMPPORT trial
by: S. Koschel, et al.
Published: (2020-07-01)

Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer
by: Cordula A. Jilg, et al.
Published: (2020-03-01)

Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
by: Lena M. Mittlmeier, et al.
Published: (2021-05-01)

Feasibility and Outcome of PSMA-PET-Based Dose-Escalated Salvage Radiotherapy Versus Conventional Salvage Radiotherapy for Patients With Recurrent Prostate Cancer
by: Marco M. E. Vogel, et al.
Published: (2021-07-01)

Choline PET based dose-painting in prostate cancer - Modelling of dose effects
by: Belka Claus, et al.
Published: (2010-03-01)

Pelvic salvage (SBRT) radiotherapy based on 68Ga-PSMA PET/CT: About a case
by: A. Slaoui, et al.
Published: (2019-03-01)

Targeted Prostate Biopsy Using 68Gallium PSMA-PET/CT for Image Guidance
by: Demetrios N. Simopoulos, et al.
Published: (2017-09-01)

Patient and region based accuracy of PSMA PET/CT in patients undergoing salvage lymphadenectomy for lymph node recurrence following primary treatment
by: G. Devos, et al.
Published: (2020-07-01)

Recent advances of PET imaging in clinical radiation oncology
by: M. Unterrainer, et al.
Published: (2020-04-01)

Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study
by: Maarten L. Donswijk, et al.
Published: (2020-08-01)

Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer
by: Paul Rogowski, et al.
Published: (2021-06-01)

Incidental Finding of a PSMA-Positive Pancreatic Cancer in a Patient Suffering from a Metastasized PSMA-Positive Prostate Cancer
by: Simon Sirtl, et al.
Published: (2021-01-01)

Patients with biochemical recurrence after radical prostatectomy and local recurrence or negative PSMA PET/CT are excellent candidates for salvage radiotherapy to the prostatic fossa
by: H.B. Luiting, et al.
Published: (2020-07-01)

Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study
by: Simon Kirste, et al.
Published: (2021-05-01)

Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on <sup>18</sup>F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression
by: Lena M. Mittlmeier, et al.
Published: (2021-03-01)

Nodal recurrence patterns on PET/CT after RTOG-based nodal radiotherapy for prostate cancer
by: C.P. Liskamp, et al.
Published: (2020-05-01)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
by: Magdalena Staniszewska, et al.
Published: (2021-07-01)

FDG-PET Versus PSMA-PET: A Patient With Prostate Cancer
by: Asim Kichloo MD, et al.
Published: (2020-07-01)

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives
by: Sebastian Zschaeck, et al.
Published: (2018-05-01)

Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI.
by: Thorsten Heußer, et al.
Published: (2017-01-01)

Clinical perspectives of PSMA PET/MRI for prostate cancer
by: Felipe de Galiza Barbosa, et al.
Published: (2018-09-01)

Correlation between hybrid PSMA PET MRI and histopathology at radical prostatectomy
by: G. Mehawed, et al.
Published: (2020-07-01)

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
by: Nat P. Lenzo, et al.
Published: (2018-02-01)

Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol
by: Jeremie Calais, et al.
Published: (2021-05-01)

Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
by: S. Rudisile, et al.
Published: (2019-08-01)

Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer
by: Wajahat Khatri, et al.
Published: (2021-04-01)

Value of <sup>18</sup>F-PSMA-PET/MRI for Assessment of Recurring Ranula
by: Felix Tilsen, et al.
Published: (2021-08-01)

Orbital and brain metastases on 68Ga-PSMA PET/CT in a patient with prostate carcinoma refractory to 177Lu-PSMA and 225Ac-PSMA therapy
by: Ashwin Singh Parihar, et al.
Published: (2021-01-01)

Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial
by: J. Ferdinandus, et al.
Published: (2020-07-01)

68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
by: Lisa H. de Vries, et al.
Published: (2020-03-01)

Clinically diagnostic value of 68Ga-PSMA PET/CT imaging for clear cell renal cell carcinoma
by: C. Zhang, et al.
Published: (2020-07-01)